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Amory and Amory correctly note that grapefruit
juice inhibits CYP3A4. Indeed, the same phenome-
non may be seen with intact grapefruit segments.
 
4
 
This effect is confined to intestinal rather than he-
patic CYP3A4, and significant increases in drug lev-
els are most likely with CYP3A4 substrates that
normally undergo a high degree of presystemic
metabolism.
 
5
 
 With the exception of cisapride (which
is no longer in widespread use), this is not the case
for most of the CYP3A4 substrates implicated in
the genesis of torsades de pointes. Nevertheless,
a recognition of the potential effects of grapefruit
on drug bioavailability is essential, given the multi-
tude of drugs metabolized by CYP3A4.
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Birth Weight and Breast Cancer
 
to the editor: 
 
Ahlgren et al. (Oct. 14 issue)
 
1
 
 re-
port the importance of both birth weight and child-
hood growth on the risk of breast cancer. Although
the authors do not provide information about
early growth (from the postnatal period to the age
of eight years) or birth length, the size of their study
permits additional analyses to enhance our under-
standing of how growth patterns relate to disease.
 
2
 
For example, were there any interactions between
birth weight and childhood body size? Underweight
babies who are well nourished in early childhood
may have a greater risk of chronic disease later in
life because of the hormonal changes that accom-
pany rapid catch-up growth.
 
3-5
 
 If so, persons with
a low birth weight and peak height at an early age
may have a greater increase in the risk of breast can-
cer than persons with a higher birth weight whose
peak height occurs later. Babies who have “catch-
down” growth may also have a different risk pro-
file. Since the effect of menarche on breast cancer
was mediated by other growth variables, models
showing how measures of growth in infancy and
early childhood are associated with markers of in-
termediate growth, including age at peak height,
would provide crucial insight into the underlying
pathways.
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to the editor: 
 
Ahlgren et al. report that birth
weight and childhood growth influence the risk
of breast cancer. We recently analyzed these rela-
tionships in a British cohort followed from birth
to the age of 53 years.
 
1,2
 
 A higher risk of breast
cancer at the age of 53 years was associated, in
multivariable models, with the gain in height be-
tween 4 and 7 years and between 11 and 15 years
and with the decrease in the body-mass index be-
tween 2 and 4 years. These effects were stronger
the earlier the age at menarche, reflecting a similar
pattern in the relationship between adult height
and the risk of breast cancer (Table 1, top of page
305). Thus, it appears that women who grew fast-
er in early childhood, had an earlier menarche,
and continued to grow during the postpubertal
period, reaching an adult height that was above av-
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erage for their age at menarche, were at greatest
risk. Our findings, although based on a limited
number of cancers in relatively young women, may
help elucidate the complex relations among child-
hood growth, the onset of menarche, and the risk
of breast cancer that are described — but not ex-
plained — in the report by Ahlgren et al.
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dr. ahlgren replies: 
 
Inspired by Dr. Terry’s com-
ments and those of Dr. De Stavola and colleagues,
we conducted a further analysis (Table 1, below);
 
* Data, which are from the Medical Research Council National Survey of Health and Development, are based on a total 
of 2187 women and 59 cases of breast cancer.
 
1 
 
BMI denotes body-mass index.
† Relative risks were estimated with the use of a logistic-regression model that included all growth components (height at 
2.0 years of age; yearly changes in height from 2.1 to 4.0 years, 4.1 to 7.0 years, 7.1 to 11.0 years, 11.1 to 15.0 years, and 
15.1 years to adulthood; BMI at 2.0 years of age; and yearly changes in BMI from 2.1 to 4.0 years, 4.1 to 7.0 years, 7.1 
to 11.0 years, and 11.1 to 15.0 years). Results are shown only for anthropometric measures for which there was evidence 
that their effect on breast cancer was modified by age at menarche.
‡Relative risks were estimated with the use of a logistic-regression model that included only adult height, age at menar-
che, and their interaction.
§ The likelihood-ratio test was used to assess linear trend in the age-at-menarche–specific relative risks.
 
¶The Wald test was used to assess the heterogeneity of the age-at-menarche–specific relative risks.
 
Table 1. Relative Risks of Breast Cancer Associated with 1-SD Increases in Anthropometric Measures at Certain Ages, 
According to the Age at Menarche.*
Age at Menarche Model with All Childhood Growth Components† Model with Adult Height‡
 
Yearly Change in 
BMI, 2.1–4.0 yr
Yearly Change in 
Height, 4.1–7.0 yr
Yearly Change in 
Height, 11.1–15.0 yr
 
relative risk (95 percent confidence interval)
 
<12.5 yr 0.50 (0.33–0.75) 1.95 (1.25–3.04) 1.66 (1.00–2.78) 1.85 (1.20–2.84)
12.5–13.4 yr 0.95 (0.54–1.65) 1.37 (0.82–2.31) 1.89 (1.13–3.15) 0.96 (0.58–1.58)
≥13.5 yr 0.89 (0.55–1.44) 1.07 (0.66–1.77) 0.76 (0.43–1.32) 1.13 (0.72–1.77)
Linear trend§ 0.01 0.001 0.01 0.02
Interaction¶ 0.02 0.07 0.13 0.04
 
* The relative risk is for each one-year increase in age at peak growth, each 5-cm increase in height, and each 1-unit in-
 
crease in the body-mass index (BMI).
 
Table 1. Association between Growth Variables and Breast Cancer, According to Birth Weight.*
Growth Variable Birth Weight
P Value
for Effect 
Modification
 
Quintile 1 Quintiles 2, 3, and 4 Quintile 5
 
relative risk (95 percent confidence interval)*
 
Age at peak growth 0.88 (0.80–0.97) 0.91 (0.86–0.97) 0.88 (0.79–0.98) 0.79
Height at age 8 1.11 (1.01–1.23) 1.13 (1.06–1.20) 1.08 (0.97–1.21) 0.80
Height increase, age 8 to age 14 1.14 (0.96–1.37) 1.15 (1.03–1.29) 1.07 (0.87–1.30) 0.80
BMI at age 14 0.91 (0.68–0.95) 0.95 (0.92–0.98) 0.94 (0.89–1.00) 0.27
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on February 19, 2014. For personal use only. No other uses without permission. 
 Copyright © 2005 Massachusetts Medical Society. All rights reserved. 
 The
 
 new england journal 
 
of
 
 medicine
 
306
 
n engl j med 
 
352;3
 
www.nejm.org january 
 
20, 2005
 
we investigated whether birth weight modified the
main results. As shown in Table 1, we found no sig-
nificant effect modification.
 
Martin Ahlgren, M.D., Ph.D.
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DK-2300 Copenhagen, Denmark
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Autoimmune Lymphoproliferative Syndrome and Perforin
 
to the editor: 
 
Clementi et al. (Sept. 30 issue)
 
1
 
 de-
scribe the occurrence of autoimmune lymphopro-
liferative syndrome (ALPS) and lymphoma in a pa-
tient carrying both a heterozygous 
 
Fas
 
 mutation and
a heterozygous mutation in the perforin gene (
 
Prf1
 
).
It is likely that, in addition to 
 
Fas
 
 mutations, associ-
ated genetic defects could contribute to the ALPS
phenotype.
 
2
 
 However, the possibility that the de-
scribed 
 
Prf1
 
 variant, which resulted in the replace-
ment of asparagine with serine at position 252 of the
perforin protein (N252S), would be such an associ-
ated factor is questionable. Although this variant
was identified in a patient with hemophagocytic
lymphohistiocytosis,
 
3
 
 two additional 
 
Prf1 
 
muta-
tions (resulting in the replacement of glycine with
arginine at position 45 [G45R] and the replacement
of glycine with serine at position 149 [G149S]) were
later found in this patient (our unpublished data),
casting doubt about the pathogenicity of the N252S
variant.
 
4
 
 In addition, this 
 
Prf1
 
 variant is found in
18 percent of healthy controls and 10 percent of pa-
tients with ALPS type I (our unpublished data). We
have also found a heterozygous 
 
Fas
 
 mutation (re-
sulting in the replacement of glycine with serine
at position 237 of Fas), together with the N252S
 
Prf1
 
 polymorphism, in a patient with ALPS and his
healthy father (Fig. 1). The absence of any disease
in the father strongly suggests that the heterozy-
gous 
 
Prf1
 
 N252S mutation in the patient described
by Clementi et al. was not pathogenetic.
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the authors reply: 
 
Rieux-Laucat et al. question the
role of the N252S perforin mutation in ALPS. We ar-
gue that it can contribute to ALPS for the follow-
ing reasons. First, the frequency of N252S cited by
Rieux-Laucat et al. is much higher than the pub-
lished data.
 
1
 
 Moreover, Rieux-Laucat et al. do not
mention the ethnic origins and actual numbers of
subjects. To date, we have found this variant in 1 of
330 Italian controls (0.3 percent).
Second, we recently found the N252S variant
in a second patient with ALPS type III who had a re-
markable defect in natural-killer-cell activity. The
frequency of N252S in patients with ALPS (2 of 25)
and in controls (1 of 330) suggests its associa-
 
Figure 1. Pedigree of the Patient.
 
The Fas mutation was inherited from the patient’s 
healthy father, whereas the Prf1 N252S variant was found 
in all members of this family.
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